Am J Transplant, Volume 5, Suppl 3 Archives - Page 24 of 170 - ATC Abstracts

2015 American Transplant Congress
Outcomes of Kidney Transplant Recipients Minimally Immunosuppressed: A Cohort Study Analysis
A.-H. Querard,^1,2,3 F. Gillaizeau,^2,1 G. Couvrat-Desvergne,^1,2,3 J. Dantal,^1,4,5 P. Daguin,¹ S. Le Floch,¹ S. Castagnet,⁶ S. Brouard,^1,4 Y. Foucher,^2,1 M. Giral.^1,2,4,5
¹Institute for Transplantation, Urology and Nephrology (ITUN), CHU Nantes, RTRS « Centaure », INSERM U1064, Université de Nantes, Nantes, France; ²EA 4275 SPHERE– Biostatistics, Pharmacoepidemiology and Human Sciences Research, Nantes University, Nantes, France; ³Centre Hospitalier Departemental de Vendée, La Roche sur Yon, France; ⁴Centre d'Investigation Clinique Biothérapie, Nantes, France; ⁵Centre Hospitalier Universitaire, Nantes, France; ⁶HLA Laboratory, Etablissement Français du Sang, Nantes, France.
Background: Renal transplantation is the treatment of choice for endstage renal disease. Nevertheless, it involves immunosuppressive treatments with Serious Adverse Events (SAE) such as infections…
2015 American Transplant Congress
Tacrolimus for the Treatment of Refractory Biopsy-Proven Acute Cellular Rejection in Patients on Belatacept-Based, CNI- and Steroid-Free Immunosuppression Regimens
K. Trobaugh,¹ A. Shields,^1,2 S. Tremblay,¹ R. Alloway,¹ M. Cardi,² D. Witte,¹ F. Paterno,¹ M. Cuffy,¹ E. Woodle.¹
¹Univ of Cincinnati, Cincinnati; ²The Christ Hospital, Cincinnati.
Background: Tacrolimus (TAC) is effective as rescue treatment (tx) in renal transplant patients (pts) on cyclosporine-based immunosuppression (IS) who have recurrent or resistant acute rejection…
2015 American Transplant Congress
Unrecognized Synchronous Hepatocellcular Carcinoma Lesions in Explanted Liver Transplant Specimens
D. Aufhauser, Jr.,¹ K. Eddinger,¹ E. Furth,² P. Abt,¹ M. Levine.¹
¹Department of Surgery, University of Pennsylvania, Philadelphia, PA; ²Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Introduction: Liver resection for early-stage hepatocellular carcinoma (HCC) is limited by high surgical risk in cirrhotics and high rates of intrahepatic recurrence. We postulated that…
2015 American Transplant Congress
Suboptimal Vaccination Coverage After Liver Transplantation: Opportunity for Improvement
L. Danziger-Isakov, S. Blum, G. Paulsen, M. Lake, R. Rengering, M. Duncan, J. Zigmond, K. Campbell, J. Bucuvalas.
Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Elimination of vaccine-preventable disease after solid organ transplantation (SOT) has the potential to improve outcomes. We evaluated immunization rates and the impact of directed recommendations…
2015 American Transplant Congress
Long-Term Follow-Up After Conversion from Twice-Daily Tacrolimus Formulation to Once-Daily Tacrolimus Formulation in Pediatric Kidney Transplantation
C. Choi, A. Han, S. Min, S.-K. Min, T. Lee, I.-M. Jung, S. Kim, J. Ha.
Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
PurposeTacrolimus is one of the most frequently used immunosuppressants in pediatric kidney transplantation (KT) as in adult. In Pediatric kidney recipients, it is more important…
2015 American Transplant Congress
Discrepancies Between the U.S. Transplant Registry and Cancer Registries Regarding Cancer Diagnoses in Transplant Recipients
E. Engels,¹ D. Segev,² J. Snyder,³ B. Kasiske,³ E. Yanik.¹
¹National Cancer Institute, Bethesda; ²Johns Hopkins Hospital, Baltimore; ³SRTR, Minneapolis.
Background: Transplant recipients have elevated cancer risk. US transplant centers report incident cancer diagnoses to the transplant network at yearly intervals, and these data are…
2015 American Transplant Congress
Industry Payments to Transplant Surgeons
R. Ahmed, E. Chow, A. Massie, E. King, B. Orandi, S. Bae, L. Nicholas, B. Lonze, D. Segev.
Johns Hopkins, Baltimore.
The Open Payments Program (OPP) was implemented to publicly disclose industry payments to physicians, enabling patients to be aware of potential conflicts of interest. Outcomes…
2015 American Transplant Congress
Human CMV-Specific CD8 T Cells Exhibit Distinct Phenotypes and Distribution Patterns in Tissues and Circulation
C. Gordon,^1,2,5 J. Thome,^1,3 G. Tomer,¹ D. Farber.^1,3,4
¹Columbia Center for Translational Immunology, Columbia University Medical Center, New York; ²Medicine, Columbia University Medical Center, New York; ³Microbiology and Immunology, Columbia University Medical Center, New York; ⁴Surgery, Columbia University Medical Center, New York; ⁵University of Melborne, Melbourne, Australia.
IntroductionCMV persists and is controlled by T cells in multiple tissues; however, study of CMV responses has largely been limited to blood containing only 2-3%…
2015 American Transplant Congress
Screening for West Nile Virus in California: Resolving IgM Anti-WNV in the Area With Dengue Seroprevalence
C. Chinchilla-Reyes,^1,2 D. Tanglao,¹ T. Mone,³ M. Koss,¹ M. Nowicki.^1,2
¹Viracor-IBT Laboratories, Los Angeles; ²Mendez National Institute of Transplantation Foundation, Los Angeles; ³OneLegacy, Los Angeles.
West Nile Virus (WNV) symptoms develop 2-15 days after exposure with a short period of viremia (6-7 days). It is possible to detect WNV in…
2015 American Transplant Congress
Long-Term Metabolic Outcomes of Functioning Pancreas Transplants in Type 2 Diabetic Recipients
S. Shin, Y. Kim, B. Choi, J. Choi, J. Jung, H. Cho, D. Han.
Asan Medical Center, Seoul, Korea.
Background Limited data are available on long-term metabolic outcomes of functioning pancreas transplants in patients with type 2 diabetes mellitus (T2DM). The aim of this…